BLCO News and Press, Bausch + Lomb Corporation From 11/30/23

2023-11-30 05:33:24 ET Summary Bausch Health has a solid business model with steady revenue generation and strong operating income margins - but debt & litigation are crippling the business. The company's heavy debt of >$20bn, and pending litigation around lead product Xifa...

2023-11-25 16:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have collected a total of 76,645,000 million units, or 464,100 pounds, of...

2023-11-08 01:20:02 ET Summary Bausch + Lomb has made two acquisitions in a short period of time. The acquisitions are huge and are financed by debt. I think Bausch + Lomb is taking unnecessary risks. However, Bausch + Lomb remains a great company with a safe and consistent ea...

2023-11-01 16:43:09 ET Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Conference Call November 1, 2023, 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brent Saunders - Chairman and Chief Executive Offi...

2023-11-01 07:25:39 ET More on Bausch + Lomb Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease Bausch + Lomb prices $1.4B notes offering Bausch + Lomb to raise debt to finance Novartis deal Seeking Alpha’s Quant Rating on Bausch + Lomb ...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

Revenues of $1.007 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million Adjusted EBITDA (non-GAAP) 1 of $187 Million Revenues Grew 7% as Reported and 8% on a Constant Currency 1 Basis Compared to the Third Quarter of 2022, Driven by Growth...

Bausch + Lomb Corporation (BLCO) is expected to report $0.18 for Q3 2023

Presentations Will Feature Studies Evaluating MIEBO™ (Perfluorohexyloctane Ophthalmic Solution), IC-8 ® Apthera™ IOL and ARMOR Surveillance Study Data Company Will Host Six Educational Events Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading glob...